Cargando…

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study

In preclinical models, IL-1β inhibition could enhance the efficacy of fluorouracil (5-FU). In this phase 2 study, we assessed the activity and safety of 5-FU plus bevacizumab and anakinra (an IL-1β and α inhibitor) in patients with metastatic colorectal (mCRC) refractory to chemotherapy and anti-ang...

Descripción completa

Detalles Bibliográficos
Autores principales:	Isambert, Nicolas, Hervieu, Alice, Rébé, Cedric, Hennequin, Audrey, Borg, Christophe, Zanetta, Sylvie, Chevriaux, Angélique, Richard, Corentin, Derangère, Valentin, Limagne, Emeric, Blanc, Julie, Bertaut, Aurélie, Ghiringhelli, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140586/ https://www.ncbi.nlm.nih.gov/pubmed/30228942 http://dx.doi.org/10.1080/2162402X.2018.1474319

Ejemplares similares

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer
por: Bellio, Hélène, et al.
Publicado: (2021)

Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
por: Fumet, Jean-David, et al.
Publicado: (2018)

HSP70 is a negative regulator of NLRP3 inflammasome activation
por: Martine, Pierre, et al.
Publicado: (2019)

Cathepsin B Is Required for NLRP3 Inflammasome Activation in Macrophages, Through NLRP3 Interaction
por: Chevriaux, Angélique, et al.
Publicado: (2020)

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
por: Grapin, Mathieu, et al.
Publicado: (2019)

Liver X Receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRβ subcellular localization
por: Courtaut, Flavie, et al.
Publicado: (2015)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
por: Fumet, Jean-David, et al.
Publicado: (2020)

Heat shock and HSP70 regulate 5-FU-mediated caspase-1 activation in myeloid-derived suppressor cells and tumor growth in mice
por: Pilot, Thomas, et al.
Publicado: (2020)

Monitoring HSP70 exosomes in cancer patients’ follow up: a clinical prospective pilot study
por: Chanteloup, Gaëtan, et al.
Publicado: (2020)

Induction of pyroptosis in colon cancer cells by LXRβ
por: Rébé, Cédric, et al.
Publicado: (2015)

Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers
por: Medjebar, Soleine, et al.
Publicado: (2020)

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer
por: Klopfenstein, Quentin, et al.
Publicado: (2021)

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma
por: Bertaut, Aurélie, et al.
Publicado: (2016)

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer
por: Roussot, Nicolas, et al.
Publicado: (2023)

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients
por: Limagne, Emeric, et al.
Publicado: (2019)

IRF8-dependent molecular complexes control the Th9 transcriptional program
por: Humblin, Etienne, et al.
Publicado: (2017)

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
por: Thibaudin, Marion, et al.
Publicado: (2023)

Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy
por: Fumet, Jean-David, et al.
Publicado: (2020)

Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer
por: Boustani, Jihane, et al.
Publicado: (2020)

Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial
por: Fumet, Jean-David, et al.
Publicado: (2017)

Protocol for simultaneous analysis of peripheral and intratumoral lymphocyte function by flow cytometry
por: Daumoine, Susy, et al.
Publicado: (2023)

Influence of primary tumor location and resection on survival in metastatic colorectal cancer
por: Tharin, Zoé, et al.
Publicado: (2020)

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
por: Kalfeist, Laura, et al.
Publicado: (2022)

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness
por: Barnestein, Robby, et al.
Publicado: (2022)

Simultaneous isolation of CD45 tumor-infiltrating lymphocytes, tumor cells, and associated fibroblasts from murine breast tumor model by MACS
por: Kalfeist, Laura, et al.
Publicado: (2023)

Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance
por: Cotte, Alexia Karen, et al.
Publicado: (2018)

Implementation and use of whole exome sequencing for metastatic solid cancer
por: Réda, Manon, et al.
Publicado: (2020)

Immunological features of coronavirus disease 2019 in patients with cancer
por: Thibaudin, Marion, et al.
Publicado: (2020)

Impact of proton therapy on antitumor immune response
por: Mirjolet, Céline, et al.
Publicado: (2021)

Downregulation of Elovl5 promotes breast cancer metastasis through a lipid-droplet accumulation-mediated induction of TGF-β receptors
por: Kieu, Trinh-Le-Vi, et al.
Publicado: (2022)

Identification of Biological Markers of Liver X Receptor (LXR) Activation at the Cell Surface of Human Monocytes
por: Rébé, Cédric, et al.
Publicado: (2012)

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma
por: Niogret, Julie, et al.
Publicado: (2020)

Interleukin-1β and Cancer
por: Rébé, Cédric, et al.
Publicado: (2020)

STAT3, a Master Regulator of Anti-Tumor Immune Response
por: Rébé, Cédric, et al.
Publicado: (2019)

Membrane-bound exosomal HSP70 as a biomarker for detection and monitoring of malignant solid tumours: a pilot study
por: Chanteloup, Gaétan, et al.
Publicado: (2020)

Combined Application of Bevacizumab and Mitomycin C or Bevacizumab and 5-Fluorouracil in Experimental Glaucoma Filtration Surgery
por: Zuo, Lei, et al.
Publicado: (2018)

Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
por: Devaux, Madeline, et al.
Publicado: (2019)

Immune effects of 5-fluorouracil: Ambivalence matters
por: Ghiringhelli, François, et al.
Publicado: (2013)

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy
por: Tharin, Zoé, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6n6k8a2fivt8lo7t07khl9nceh